Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Net Cash Flow (2016 - 2025)

Anaptysbio (ANAB) has disclosed Net Cash Flow for 10 consecutive years, with $128.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 287.39% year-over-year to $128.4 million, compared with a TTM value of $115.1 million through Dec 2025, up 32.14%, and an annual FY2025 reading of $115.1 million, up 32.14% over the prior year.
  • Net Cash Flow was $128.4 million for Q4 2025 at Anaptysbio, up from $65.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $159.3 million in Q4 2021 and bottomed at -$329.3 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$616000.0, with a median of $11.2 million recorded in 2022.
  • The sharpest move saw Net Cash Flow tumbled 1077.43% in 2022, then soared 1443.96% in 2024.
  • Year by year, Net Cash Flow stood at $159.3 million in 2021, then crashed by 91.99% to $12.8 million in 2022, then decreased by 24.22% to $9.7 million in 2023, then plummeted by 808.39% to -$68.5 million in 2024, then surged by 287.39% to $128.4 million in 2025.
  • Business Quant data shows Net Cash Flow for ANAB at $128.4 million in Q4 2025, $65.5 million in Q3 2025, and -$54.3 million in Q2 2025.